Simner Patricia J, Pitout Johann D D, Dingle Tanis C
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Clin Microbiol Rev. 2024 Dec 10;37(4):e0005422. doi: 10.1128/cmr.00054-22. Epub 2024 Nov 15.
SUMMARYThe carbapenems remain some of the most effective options available for treating patients with serious infections due to Gram-negative bacteria. Carbapenemases are enzymes that hydrolyze carbapenems and are the primary method driving carbapenem resistance globally. Detection of carbapenemases is required for patient management, the rapid implementation of infection prevention and control (IP&C) protocols, and for epidemiologic purposes. Therefore, clinical and public health microbiology laboratories must be able to detect and report carbapenemases among predominant Gram-negative organisms from both cultured isolates and direct from clinical specimens for treatment and surveillance purposes. There is not a "one size fits all" laboratory approach for the detection of bacteria with carbapenemases, and institutions need to determine what fits best with the goals of their antimicrobial stewardship and IP&C programs. Luckily, there are several options and approaches available for clinical laboratories to choose methods that best suits their individual needs. A laboratory approach to detect carbapenemases among bacterial isolates consists of two steps, namely a screening process (, not susceptible to ertapenem, meropenem, and/or imipenem), followed by a confirmation test (, phenotypic, genotypic or proteomic methods) for the presence of a carbapenemase. Direct from specimen testing for the most common carbapenemases generally involves detection rapid, molecular approaches. The aim of this article is to provide brief overviews on Gram-negative bacteria carbapenem-resistant definitions, types of carbapenemases, global epidemiology, and then describe in detail the laboratory methods for the detection of carbapenemases among Gram-negative bacteria. We will specifically focus on the , and complex.
摘要
碳青霉烯类药物仍然是治疗革兰氏阴性菌严重感染患者的一些最有效选择。碳青霉烯酶是水解碳青霉烯类药物的酶,是全球范围内导致碳青霉烯类耐药的主要方式。检测碳青霉烯酶对于患者管理、感染预防与控制(IP&C)方案的快速实施以及流行病学目的而言是必需的。因此,临床和公共卫生微生物实验室必须能够从培养分离株以及直接从临床标本中检测并报告主要革兰氏阴性菌中的碳青霉烯酶,以用于治疗和监测目的。对于检测携带碳青霉烯酶的细菌,不存在“一刀切”的实验室方法,各机构需要确定哪种方法最符合其抗菌药物管理和IP&C计划的目标。幸运的是,临床实验室有多种选择和方法可供选择,以找到最适合其个体需求的方法。检测细菌分离株中碳青霉烯酶的实验室方法包括两个步骤,即筛选过程(对厄他培南、美罗培南和/或亚胺培南不敏感),随后是针对碳青霉烯酶存在情况的确认试验(表型、基因型或蛋白质组学方法)。直接从标本检测最常见的碳青霉烯酶通常涉及快速的分子方法。本文旨在简要概述革兰氏阴性菌对碳青霉烯类耐药的定义、碳青霉烯酶的类型、全球流行病学,然后详细描述检测革兰氏阴性菌中碳青霉烯酶的实验室方法。我们将特别关注[具体内容缺失]和[具体内容缺失]复合体。